Coagulation parameters, plasma clot optical density, and results of DNA analysis for fibrinogen Paris V
| Family member* . | PTT (sec) . | PT (sec) . | TT (sec) . | RT (sec) . | Fibrinogen (mg/dL) . | Paris V mutation . | ΔOD 405 nm . | |
|---|---|---|---|---|---|---|---|---|
| Clauss . | Antigen . | |||||||
| Normal | 25-38 | 11-15 | 19-23 | 18.5-23 | 150-350 | Negative | 0.60 ± 0.11 | |
| II.5 | 46.1 | 37.5† | 30 | 53 | 388 | 420 | Positive‡ | 0.04 |
| III.1 | 34.9 | 12.7 | 30 | 57 | 258 | 314 | Positive | 0.13 |
| III.2 | 29.3 | 13.1 | 23 | 44 | 268 | 274 | Positive | 0.06 |
| III.3 | 28.8 | 13.4 | 29 | 50 | 190 | 186 | Positive | −0.02 |
| III.4 | 30.7 | 13.9 | 34 | 43 | 258 | Positive | ||
| III.11 | 44.3 | 30.2† | 30 | 50 | 306 | 406 | Positive | −0.02 |
| IV.1 | 30.9 | 12.8 | 29 | 50 | 197 | 188 | Positive | 0.02 |
| IV.2 | 25.3 | 12.6 | 22 | 22 | 283 | 272 | Negative | 0.67 |
| IV.31-153 | Positive | |||||||
| IV.5 | 30.0 | 13.3 | 20 | 30 | 182 | 186 | Positive | 0.13 |
| IV.6 | 31.5 | 13.4 | 20 | 20 | 232 | 232 | Negative | 0.50 |
| IV.8 | 28.4 | 13.8 | 20 | 20 | 314 | 272 | Negative | 0.59 |
| IV.10 | 29.6 | 14.5 | 36 | 42 | 211 | Positive | ||
| IV.13 | 35.4 | 24.9† | 37 | 49 | 227 | 244 | Positive | 0.00 |
| Family member* . | PTT (sec) . | PT (sec) . | TT (sec) . | RT (sec) . | Fibrinogen (mg/dL) . | Paris V mutation . | ΔOD 405 nm . | |
|---|---|---|---|---|---|---|---|---|
| Clauss . | Antigen . | |||||||
| Normal | 25-38 | 11-15 | 19-23 | 18.5-23 | 150-350 | Negative | 0.60 ± 0.11 | |
| II.5 | 46.1 | 37.5† | 30 | 53 | 388 | 420 | Positive‡ | 0.04 |
| III.1 | 34.9 | 12.7 | 30 | 57 | 258 | 314 | Positive | 0.13 |
| III.2 | 29.3 | 13.1 | 23 | 44 | 268 | 274 | Positive | 0.06 |
| III.3 | 28.8 | 13.4 | 29 | 50 | 190 | 186 | Positive | −0.02 |
| III.4 | 30.7 | 13.9 | 34 | 43 | 258 | Positive | ||
| III.11 | 44.3 | 30.2† | 30 | 50 | 306 | 406 | Positive | −0.02 |
| IV.1 | 30.9 | 12.8 | 29 | 50 | 197 | 188 | Positive | 0.02 |
| IV.2 | 25.3 | 12.6 | 22 | 22 | 283 | 272 | Negative | 0.67 |
| IV.31-153 | Positive | |||||||
| IV.5 | 30.0 | 13.3 | 20 | 30 | 182 | 186 | Positive | 0.13 |
| IV.6 | 31.5 | 13.4 | 20 | 20 | 232 | 232 | Negative | 0.50 |
| IV.8 | 28.4 | 13.8 | 20 | 20 | 314 | 272 | Negative | 0.59 |
| IV.10 | 29.6 | 14.5 | 36 | 42 | 211 | Positive | ||
| IV.13 | 35.4 | 24.9† | 37 | 49 | 227 | 244 | Positive | 0.00 |
PTT, partial thromboplastin time; PT, prothrombin time; TT, thrombin time; RT, reptilase time.
Numeric designation for family members is derived from the pedigree in Figure 1.
Indicates that the prothrombin time is prolonged because the patient was on warfarin.
Positive indicates that the patient is heterozygous for the fibrinogen Paris V mutation.
Patient IV.3 died before plasma could be obtained for determining coagulation parameters. A tube of frozen whole blood was available for DNA extraction. He is not a carrier of the factor V Leiden or prothrombin gene 20210 G → A polymorphisms.